InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) CEO Discusses Medicare Reimbursement Approval for CARE Oral Medical Devices in Proactive Interview
April 10, 2024
Vivos Therapeutics (NASDAQ: VVOS), a leading medical-device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders, is spotlighted in a recent Proactive interview. During the interview, Vivos CEO Kirk Huntsman and Proactive host Steve Darling discuss the latest news from the company, which is the regulatory […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Achieves Milestone with CARE Oral Medical Devices Gaining Approval for Medicare Reimbursement
April 9, 2024
Vivos Therapeutics (NASDAQ: VVOS), a leading medical-device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders, has obtained all required regulatory approvals so that its CARE oral medical devices can be reimbursed by Medicare. Calling this a “milestone achievement,” the company noted that millions of Medicare […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Q4, FY 2023 Financial Report, Operational Update
April 1, 2024
Vivos Therapeutics (NASDAQ: VVOS), a leading medical-device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders, is reporting financial results and operating highlights for Q4 and full year 2023, for the period ended Dec. 31, 2023. The report noted that revenue came in at $3.2 million […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Schedules Release of Q4 and FY 2023 Results, Conference Call
March 28, 2024
Vivos Therapeutics (NASDAQ: VVOS) is a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (“OSA”) in adults). The company today announced it plans to release its fourth quarter and full year 2023 financial results […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Exercise of Warrants for ~$4M
February 15, 2024
Vivos Therapeutics (NASDAQ: VVOS) is a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (“OSA”)). The company today announced its entry into a definitive agreement for the immediate exercise of an outstanding common stock […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) CEO Highlights Favorable Market Developments Creating New Opportunities
February 13, 2024
Vivos Therapeutics (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders, including all severities of obstructive sleep apnea (“OSA”) in adult patients, was spotlighted in a recent Proactive interview. During the interview, Vivos Therapeutics CEO Kirk Huntsman talked with Proactive […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Notes Key Market Developments Resulting in Growth Opportunities
February 6, 2024
Vivos Therapeutics (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders, including all severities of obstructive sleep apnea (“OSA”) in adult patients, has noted significant favorable market developments resulting in opportunities for the company to reach out to more potential […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Reports Record Numbers Following First-Ever FDA 510(k) Clearance of Proprietary Oral Medical Devices
January 8, 2024
Vivos Therapeutics (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders, including all severities of obstructive sleep apnea (“OSA”), has seen significant positive numbers since it received FDA 5109k) clearance of its CARE oral medical devices. The approval was the […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) to Host Pioneering Conference for Women in Medical, Dental Sectors
December 11, 2023
Vivos Therapeutics (NASDAQ: VVOS), a leading medical-device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders, is hosting a groundbreaking event for women in the medical and dental fields. The company announced that it is hosting a conference titled “Empowering Women to Champion Airway.” Scheduled for […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) CEO Discussed ‘Breakthrough’ FDA Clearance in Proactive Interview
November 30, 2023
Vivos Therapeutics (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders, is featured in a recent Proactive Investors interview. According to the announcement, Vivos Therapeutics CEO Kirk Huntsman joined Proactive host Steve Darling to discuss a “milestone” moment for the […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces First-Ever FDA Clearance for Treatment of Severe Obstructive Sleep Apnea Using Oral Device
November 29, 2023
Vivos Therapeutics (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders, has been granted 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) for treating severe obstructive sleep apnea (“OSA”) in adults using the exclusive Vivos removable Complete Airway […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Financial Report, Operational Update for Q3 2023
November 15, 2023
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild-to-moderate obstructive sleep apnea (“OSA”) and snoring in adults, is reporting financial results and operating highlights for the third-quarter and nine-month period ending Sept. 30, 2023. Highlights of the report include revenue of $3.3 million […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Plans to Release Q3 2023 Financial Results, Schedules Earnings Update
November 10, 2023
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild-to-moderate obstructive sleep apnea (“OSA”) and snoring in adults, is planning to release its Q3 2023 financial results after market close on Tuesday, Nov. 14, 2023. In addition, the company has scheduled a conference call […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Closing of Million-Dollar Private Placement
November 3, 2023
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild-to-moderate obstructive sleep apnea (“OSA”) and snoring in adults, has closed its previously announced private placement. According to the announcement, the placement will result in approximately $3.5 million net proceeds for the company after offering […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Pricing of $4M Private Placement
October 31, 2023
Vivos Therapeutics (NASDAQ: VVOS) is a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild-to-moderate obstructive sleep apnea (“OSA”) and snoring in adults. The company has announced its entry into a securities purchase agreement with an institutional investor for the purchase and sale of 980,393 shares of its […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) to Effect a Reverse Stock Split
October 26, 2023
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from mild-to-moderate obstructive sleep apnea (“OSA”) and snoring in adults, today announced that it will effect a 1-for-25 reverse stock split of its issued and outstanding common stock, effective with the opening of trading on Friday, Oct. 27, 2023. […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Partners with Lincare in New Nationwide Distribution Deal
October 24, 2023
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from a variety of health conditions, many of which are associated with breathing-related sleep conditions arising from certain dentofacial abnormalities, has signed a U.S. nationwide distribution agreement with Lincare. The two companies have been […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) New Middle East-North Africa Distribution Deal Spotlighted in Proactive Interview
October 12, 2023
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from a variety of health conditions, many of which are associated with breathing-related sleep conditions arising from certain dentofacial abnormalities, is spotlighted in a recent Proactive feature interview. During the interview, Vivos Therapeutics CEO […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Launch of DNA Clinical Trial
October 11, 2023
Vivos Therapeutics (NASDAQ: VVOS) is a medical technology company focused on developing innovative treatments for patients suffering from mild-to-moderate obstructive sleep apnea (“OSA”) and snoring in adults. The company today announced that its flagship daytime-nighttime appliance (“DNA”) will be tested in a clinical trial at Stanford Medicine. According to the update, the protocol has been […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Strategic Collaboration, Expansion into MENA Region
October 5, 2023
Vivos Therapeutics (NASDAQ: VVOS) is a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary oral appliances for the treatment of breathing-related sleep disorders. The company today announced its entry into an exclusive distribution agreement with NOUM DMCC (“Noum”), a Dubai-based company focused on diagnostic testing and treatment […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Enters New Strategic Agreements with Ormco and On Demand Orthodontist
October 4, 2023
Vivos Therapeutics (NASDAQ: VVOS) is a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary oral appliances for the treatment of breathing-related sleep disorders. The company today announced two key strategic agreements that will expand Vivos’ current product line and are expected to create near-term additional revenue opportunities. […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces NYT Best-Selling Author James Nestor as Keynote Speaker for Upcoming Breathing Wellness Conference
October 2, 2023
Vivos Therapeutics (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective, proprietary oral appliances for the treatment of breathing-related sleep disorders, today announced that world renowned author James Nestor will headline a multidisciplinary list of distinguished speakers at the Company’s Fifth Annual Breathing Wellness Conference. This […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Q2, YTD 2023 Financial, Operational Report
August 17, 2023
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from a variety of health conditions, many of which are associated with breathing related sleep conditions arising from certain dentofacial abnormalities, is reporting its financial and operating results for the second quarter and six-month […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Date for Rescheduled Q2 2023 Financial Results Conference Call
August 16, 2023
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from a variety of health conditions, many of which are associated with breathing related sleep conditions arising from certain dentofacial abnormalities, has announced the date for the conference call to discuss financial results for […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Plans to Reschedule Q2 2023 Financial Results Conference Call
August 15, 2023
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from a variety of health conditions, many of which are associated with breathing related sleep conditions arising from certain dentofacial abnormalities, has rescheduled its conference call to discuss financial results for the second quarter […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Plans to Release Q2 2023 Financial Numbers, Schedules Conference Call
August 11, 2023
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from a variety of health conditions, many of which are associated with breathing-related sleep issues arising from certain dentofacial abnormalities, anticipates releasing its second quarter 2023 financial results on Aug. 14, 2023, after the […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Q1 2023 Financial Numbers, Corporate Update
June 9, 2023
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from a variety of health conditions, many of which are associated with breathing-related sleep issues arising from certain dentofacial abnormalities, has released a financial report and company update for the first quarter, the period […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Plans to Release Q1 2023 Financial Numbers, Host Earnings Call
June 7, 2023
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from a variety of health conditions, many of which are associated with breathing-related sleep issues arising from certain dentofacial abnormalities, anticipates releasing its first quarter 2023 financial results on June 8, 2023, after the […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Featured in Proactive Studio Podcast
May 16, 2023
Vivos Therapeutics (NASDAQ: VVOS) chairman and CEO Kirk Huntsman recently joined Natalie Stoberman from the Proactive Studio to discuss how the company’s POD device performed a highly effective rate in treating migraine headaches in a clinical study. During the interview, Huntsman said that the study showed 92% of patients reporting complete resolution of their symptoms, […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces New Strategic Initiatives
May 9, 2023
Vivos Therapeutics (NASDAQ: VVOS) today announced it has implemented a broad set of initiatives aimed at improving operational efficiencies, reducing expenses and positioning Vivos to take advantage of current growth opportunities. According to the update, the initiatives touch most aspects of Vivos’ operations and include expense reductions, product suite expansion and organizational changes that included […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Reports on ‘Game-Changing’ Appliance Treatment for Migraines
May 1, 2023
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from a variety of health conditions, many of which are associated with breathing related sleep issues arising from certain dentofacial abnormalities, is reporting on the results of a recent clinical observational study. According to […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Q4, FY Financial and Operational Report
March 31, 2023
Vivos Therapeutics (NASDAQ: VVOS), a medical device and technology company that delivers training and a full line of highly effective proprietary oral appliances for the treatment of breathing related sleep disorders in adults, including mild-to-moderate obstructive sleep apnea (“OSA”) and snoring, is reporting its financial results and operating highlights for the fourth quarter and full […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Schedules Release of Q4 and FY 2022 Results, Conference Call
March 30, 2023
Vivos Therapeutics (NASDAQ: VVOS) is a medical device and technology company that delivers training and a full line of highly effective proprietary oral appliances for the treatment of breathing related sleep disorders in adults. The company announced plans to release its fourth quarter and full year 2022 financial results after market close today, Thursday, March […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) to Participate at 35th Annual ROTH Conference
March 8, 2023
Vivos Therapeutics (NASDAQ: VVOS) is a medical device and technology company that delivers training and a full line of highly effective proprietary oral appliances for the treatment of breathing-related sleep disorders in adults. The company today announced that its chairman and CEO Kirk Huntsman and CFO Brad Amman will participate at the 35th Annual ROTH […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Expands Product Portfolio, Revenue Potential Through Strategic Acquisition
March 1, 2023
Vivos Therapeutics (NASDAQ: VVOS), a medical device and technology company that delivers training and a full line of highly effective proprietary oral appliances for the treatment of breathing related sleep disorders, today announced its acquisition of certain U.S. and international patents, product rights and other miscellaneous intellectual property from Advanced Facialdontics LLC (“AFD”), which holds […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Participation at Emerging Growth Conference
February 22, 2023
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”) and snoring in adults, will be presenting at today’s Emerging Growth Conference. The company announced that chair and CEO Kirk Huntsman will be participating in the conference; Huntsman’s […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Regains Compliance with Nasdaq Listing Requirements
January 20, 2023
Vivos Therapeutics (NASDAQ: VVOS) is focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild-to-moderate obstructive sleep apnea (“OSA”) and snoring in adults. The company today announced its receipt of a notice from the listing qualifications department of the Nasdaq Stock Market informing Vivos it has regained compliance with the minimum bid […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Closing of $8M Private Placement
January 10, 2023
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (OSA) and snoring in adults, has closed on its previously announced private placement. The placement was with a single institutional investor and resulted in approximately $8 million in gross […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Enters into Private Placement Agreement
January 5, 2023
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (OSA) and snoring in adults, has entered into a definitive agreement. According to the announcement, the agreement is with a single institutional investor and is estimated to raise $8 […]
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces FDA Clearance of Proprietary Oral Appliance for Obstructive Sleep Apnea Treatment
January 4, 2023
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (“OSA”) and snoring in adults, has received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) for its own daytime-nighttime appliance (“DNA”). According to the announcement, the clearance for […]